The Effect of Doxycycline on Matrix Metalloproteinase Expression and Activity in the Abdominal Aneurysm

Leiden University Medical Center (LUMC)

Status and phase: Completed; Phase 2

Conditions: Aortic Aneurysm, Abdominal

Treatments: Drug: doxycycline

Study type: Interventional

Funder types: Other

Identifiers

NCT00538967

P00.146

Details and patient eligibility

About

The matrix metalloproteinase-9 (MMP-9) is considered to play a central role in abdominal aortic aneurysm (AAA) initiation. Doxycycline has direct MMP-9 inhibiting properties in vitro, and it effectively suppresses AAA development in rodents. Observed inhibition of AAA progression, and contradictory findings in human studies evaluating the effect of doxycycline therapy on aortic wall MMP-9 suggest that the effects of doxycycline extend beyond MMP-9 inhibition, and that the effect may be dose dependent.

Full description

In this clinical trial, we evaluated the effect of two weeks of low (50 mg/day), medium (100 mg/day) or high dose (300 mg/day) doxycycline versus no medication in patients undergoing elective AAA repair. The effect of doxycycline treatment on MMP and cysteine proteases, and their respective inhibitors was evaluated in an integrative approach.

Enrollment: 60 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Elective open aneurysm repair

Exclusion criteria

• Severe kidney and liver dysfunction

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 4 patient groups

1

No Intervention group

2

Active Comparator group

Description:

doxycycline 50 mg/day

Treatment:

Drug: doxycycline

3

Active Comparator group

Description:

doxycycline 100 mg

Treatment:

Drug: doxycycline

4

Active Comparator group

Description:

doxycycline 300 mg

Treatment:

Drug: doxycycline